Introduction: Cefazolin is commonly used to
Enterobacteriaceae. We aimed to determine the variability of cefazolin exposure in interstitial fluid (ISF) of tissue and evaluate its dosing recommendations. Methods: Population pharmacokinetics were performed to co-model serum and ISF concentration data from six patients enrolled in a previous in vivo microdialysis study. A 5,000 patient Monte Carlo simulation was then conducted for 1 and 2 g every 8 h (q8h) regimens to calculate the penetration ratio and probability of target attainment (PTA) at 30% and 50% of the dosing interval that free drug concentrations remain above the minimum inhibitory concentration (fT[MIC) in ISF of tissue. for 30% and 50% fT[MIC targets, respectively, which decreased to 87% and 71% at 2 mg/L. For the same respective targets, a 2 g q8h dosing regimen increased PTA to 96% and 91% at 2 mg/L.
Conclusion:
Cefazolin penetration into the ISF of a lower limb infection varied across this simulated patient population. Based on these data, a 1 g q8h regimen should be sufficient to obtain 30% fT[MIC exposure against most MSSA causing cSSTI. However, a 2 g q8h dose is required to obtain 50% fT[MIC pharmacodynamic targets at the current breakpoint for Enterobacteriaceae (2 mg/L).
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INTRODUCTION
Methicillin-susceptible Staphylococcus aureus (MSSA) is one of the most common causes of complicated skin and soft tissue infection (cSSTI) [1] . Among deeper cSSTI and those located in the lower limb of diabetic patients, Gram-negative bacilli, Escherichia coli, Klebsiella pneumoniae, and Proteus species, are also commonly isolated [1, 2] . Based on this epidemiology, intravenous cefazolin has often been used to treat cSSTI for organisms proven susceptible in the hospital settings. However, dosing recommendations vary based on source and organism. Current US labeling for cefazolin includes a variety of dosing regimens as low as 250 mg every 8 h (q8h) up to 2 g q8h [3] . [5] [6] [7] .
Initially, it was lowered from B8 mg/L to B1 mg/L in 2010 with the advent of in vitro susceptibility, pharmacodynamic, and clinical outcome data. It was then readjusted to B2 mg/ L in 2011 with the recommendation of a 2 g q8h dosing regimen, so that it could still be a viable option for Enterobacteriaceae without intrinsic chromosomal cephalosporinases [7] .
In an effort to quantify drug concentrations in the interstitial fluid ( 
METHODS

Patient Population and Setting
Included patients were those from the aforementioned in vivo microdialysis study,
which was an open-label pharmacokinetic study at Hartford Hospital, Hartford, CT, USA [8] .
Inclusion criteria were hospitalized adult patients (age C18 years) with lower extremity wound infections requiring surgical debridement and defined as mild or moderate by the Infectious Diseases Society of America or as grade 2 or 3 by the International Consensus on the Diabetic Foot [10] . Patients with hypersensitivity to anesthetics (lidocaine or lidocaine derivatives), pregnancy or breastfeeding, no palpable pedal pulses, likelihood to require multiple procedures during the study, participation in another study of an investigational drug or device within the preceding 30 days, and patients with renal dysfunction, defined as an estimated creatinine clearance (CrCl) less than 50 mL/min, were excluded. The analysis in this article is based on a previously conducted study and does not involve any new studies with human or animal subjects performed by any of the authors.
Drug Administration
All patients received intravenous cefazolin over 30 or 60 min for their lower extremity wound infections via a peripheral catheter placed in the arm or a peripherally inserted central catheter (PICC). All patients included in this analysis received 1 g q8h dosing.
Sampling and Determination of Cefazolin Concentrations
Venous blood samples (7-9 per patient) were collected at various time points from a peripheral intravenous catheter or PICC after a minimum of four doses (i.e., steady state).
Sampling time points included immediately prior to and after the infusion, several points hourly after the infusion, and then just prior to the next dose. Dialysate samples of *120 lL were obtained from the microdialysis catheters at each of the corresponding blood sample time points. Microdialysis catheters were calibrated for each patient after sampling by using the in vivo retrodialysis technique [11] . Cefazolin concentrations in serum and ISF were quantified by a validated high-performance liquid chromatography assay [12] .
Population Pharmacokinetics
Cefazolin serum and ISF concentrations were co-modeled by the non-parametric adaptive grid (NPAG) with adaptive gamma algorithm available in the Pmetrics package for R (LAPK, Los Angeles, CA, USA) [13] . A total of 53 serum and 53 ISF concentrations from six patients were used, and individual concentrations were weighted by the reciprocal of assay variance multiplied by gamma. Weighting based on interday assay variance was employed using a plot of the assay standard deviation (SD) versus measured cefazolin concentrations, which was best described by the equations: SD serum = c(0.0071 ? 0.0449 9 C1) and SD ISF = c(0.0002 ? 0.0560 9 C2), where C1 and C2 are cefazolin concentrations in serum and ISF, respectively, and c was identified as 3.76. Mean values were used as the measure of central tendency for population parameter estimates. Bayesian estimates were obtained for each patient using the population-of-one utility within Pmetrics.
Both two-and three-compartment models were explored, with one of the compartments being the sampled ISF. Multiple models were evaluated and discriminated employing the Akaike Information Criterion (AIC) [14] 
RESULTS
Patient Characteristics
A total of six patients were included in this analysis. Five out of six patients were male and their age ranged from 35 to 83 years with a mean ± SD of 55 ± 17 years ( (Fig. 2b) .
The mean ± SD and median penetration ratios for the six included patients based on their individual Bayesian parameter estimates were 0.90 ± 0.48 and 0.72, respectively.
Monte Carlo Simulation
Parameter estimates from the Pmetrics semiparametric simulator recapitulated the mean, SD, and median estimates of the original model.
The mean ± SD and median penetration ratios for 5,000 simulated patients were 1.36 ± 4.57 and 0.80, respectively. The 5th and 95th
percentiles for simulated penetration into ISF were 0.15 and 2.74, respectively. PTA results for serum and ISF exposures of 30%, 50%, and 100% fT[MIC are provided in Table 3 .
DISCUSSION
The previously published cefazolin in vivo microdialysis study by our group evaluated ISF concentrations of intravenously administered Table 2 Final parameter estimates from the population pharmacokinetic model Cefazolin CL in this population was also similar to most other reported values. van Kralingen and colleagues [17] have reported CL of 4.2 ± 0.1 L/h in patients with average ± SD age of 44 ± 11 years, TBW of 151 ± 35 kg, and BMI of 51 ± 10 kg/m 2 after a single prophylactic dose of 2 g prior to bariatric surgery. They also observed CL had a significant negative correlation with age, but not with concentrations and is therefore not directly comparable. Nonetheless, this unbound CL estimate is feasible because cefazolin is highly protein bound; protein binding in our six patients was 85%.
The observed mean ± SD and median penetration ratios from our six patients using their individual Bayesian parameter estimates were 0.90 ± 0.48 and 0.72 (range 0.61-1.87), respectively; these values were similar to the original observed penetration ratios based on trapezoidal rule: 1.21 ± 0.67 and 0.90 (range 0.7-2.68), respectively [8] . The Monte Carlo simulation incorporates variability between patients in the pharmacokinetic estimates, and as a result, the mean ± SD and median simulated penetration ratios were 1.36 ± 4.57 and 0.80, respectively. These penetration ratio are comparable with the values observed by Brill [18] reported 85% penetration (range 78-106%). Taken collectively, these data consistently suggest that there is the potential for a wide range in the estimate for cefazolin penetration into ISF, which may unpredictably be greater than or less than exposures in serum.
While penetration ratio was calculated to display the relative exposure of cefazolin in ISF of tissue versus in serum, the pharmacodynamic target of interest for the efficacy of cefazolin in ISF remains fT[MIC [20] [21] [22] . Although the cefazolin target fT[MIC in ISF needed for efficacy against MSSA and Enterobacteriaceae are unknown, 30% for MSSA [22] [23] [24] and 50%
for Enterobacteriaceae [22, 25, 26] were employed as these are targets required in blood. A target of 100% fT[MIC was also included for comparison. Consistent with current breakpoints, where applicable, PTAs for cefazolin 1 g q8h in serum were high at MICs of 1 mg/L and 2 mg/L (Table 3a) .
However, analysis of exposure probabilities in tissue revealed much lower PTA results. At the MIC 90 for MSSA of 1 mg/L, the PTA for a 1 g q8h dose in ISF was 96% using the 30% fT[MIC target (Table 3b) . At an MIC of 2 mg/L, the current-susceptible breakpoint for Enterobacteriaceae, a 1 g q8h regimen obtained a PTA of 71% for 50% fT[MIC (Table 3b ), but a 2 g q8h dosing regimen increased the PTA to 91% for the same target (Table 3b) . PTAs for 50% fT[MIC in tissue from our study for the 2 g dose are comparable with PTAs reported by Brill and colleagues [19] : 96% and 91% (Table 3b) 
